Iron overload disorders are a heterogeneous group of conditions in which the body accumulates iron beyond the capacity of normal storage and excretion - resulting in tissue iron deposition, oxidative damage and progressive organ dysfunction. Chronic transfusional iron overload is the indication for which deferasirox is most widely used.
Why Iron Overload Matters #
The human body has no regulated mechanism for excreting iron. Once iron is absorbed (or transfused), it is retained until lost passively through cell turnover. In conditions requiring repeated red-cell transfusions, each unit delivers approximately 200 mg of elemental iron. Within months to a few years, this exceeds the body's safe storage capacity, with iron depositing first in the liver, then heart, pancreas and pituitary.
Mechanisms of Tissue Damage #
Excess iron drives Fenton-chemistry generation of hydroxyl radicals from cellular hydrogen peroxide. The resulting oxidative damage produces lipid peroxidation, mitochondrial dysfunction and progressive fibrosis. Cardiomyocytes are particularly vulnerable; cardiac iron loading is historically the leading cause of mortality in untreated transfusion-dependent thalassemia.
Major Iron Overload Conditions #
| Condition | Mechanism of Iron Overload |
|---|---|
| Beta-thalassemia major | Lifelong red-cell transfusion + ineffective erythropoiesis driving increased intestinal iron absorption |
| Sickle-cell disease (SCD) | Chronic transfusion programmes for stroke prevention and selected complications |
| Myelodysplastic syndromes (MDS) | Transfusion dependence in lower-risk MDS; ineffective erythropoiesis |
| Diamond-Blackfan anemia & rare anemias | Lifelong transfusion support |
| Hereditary haemochromatosis | HFE / non-HFE genetic dysregulation of hepcidin - primary increased absorption (chelation usually second-line) |
| Aceruloplasminaemia & atransferrinaemia | Rare inherited disorders of iron handling proteins |
Diagnosis & Monitoring #
- Serum ferritin: initial screening and monitoring (subject to inflammation-related elevations)
- Transferrin saturation: useful in primary haemochromatosis
- Liver iron concentration (LIC): measured by MRI R2 or T2* (gold standard non-invasive measure)
- Cardiac T2* MRI: assesses myocardial iron loading; values < 20 ms indicate cardiac iron risk
- Endocrine screening: for hypogonadism, hypothyroidism, diabetes - particularly in long-standing thalassemia
Therapeutic Options #
| Approach | Notes |
|---|---|
| Iron chelation - oral (deferasirox) | Once-daily; standard of care in transfusional overload |
| Iron chelation - oral (deferiprone) | Three-times-daily; selected indications |
| Iron chelation - parenteral (deferoxamine) | Subcutaneous infusion; historical mainstay; reserved for selected cases |
| Phlebotomy | First-line in non-anemic primary haemochromatosis |
Public-Health & Procurement Perspective #
Across LATAM, Africa, Asia and CIS, transfusion-dependent disorders represent a significant patient burden. Reliable, regulator-compliant access to oral iron chelators such as DEFRATAJ is therefore a public-health priority for ministries of health, NGOs and tender programmes. Taj Pharma supplies DEFRATAJ in five strengths to support these programmes - see the Why Choose Taj Pharma page for procurement details.